German pharmaceutical giant Merck KGaA has opened a viral clearance (VC) laboratory as part of the first phase of a new EUR 29 million ($28.5 million) China Biologics Testing Center in Shanghai. The 5,000 square meter center is the first of its kind for Merck in China and is designed to meet the growing demand for VC testing services in the country.
Laboratory Capabilities and Services
The VC laboratory enables customers to conduct viral clearance studies locally, from pre-clinical development to commercialization. This facility is expected to meet the double-digit demand for VC testing services in China, providing a significant boost to the local biologics industry.
Future Expansion and Global Network
The second phase of the center’s facilities is scheduled to open in late 2023 and will offer cell line characterization and lot release testing services. The Shanghai facility joins Merck’s global viral clearance suites network, which includes sites in Singapore, Stirling (UK), and Rockville, Maryland (US). These facilities share the same global expertise, standards, and operating systems, ensuring consistent quality and service delivery worldwide.
Future Outlook
The opening of the viral clearance laboratory in Shanghai marks a significant step in Merck’s global expansion strategy. By enhancing its presence in China, Merck aims to support the local biologics industry and meet the increasing demand for high-quality testing services, ultimately contributing to the development of innovative biologic therapies.-Fineline Info & Tech
